DHR · Danaher Corp
Price
Snapshot
50 fields · last close| Market Cap | $161.0B |
| P/E | 40.21 |
| Float | 626.6M |
| Beta | 0.79 |
| Volatility | 19.7% |
| Exchange | NYSE |
| Sector | Life Sciences Tools & Services |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 75.5 |
| Price | 225.06 |
| Change | −1.74% |
| Prev Close | 229.04 |
| Open | 230.50 |
| Day Low | 228.36 |
| Day High | 231.93 |
| Avg Vol | 4 |
| Avg $ Vol | $943.4M |
| 52W High | 242.80 |
| 52W Low | 160.93 |
| 52W Pos | 78.3% |
| From High | −7.31% |
| From Low | +39.85% |
| Max DD 1Y | −33.11% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | +1.62% |
| SMA 50 | +5.22% |
| SMA 200 | +11.94% |
| RSI (14) | 62.5 |
| Vol 30D | 28.3% |
| Vol 90D | 36.0% |
| 1Y Range | 161–243 |
| Daily bars | 537 |
| Perf Week | +4.20% |
| Perf Month | +7.78% |
| Perf Quarter | +13.89% |
| Perf Half Y | +17.16% |
| Perf Year | +8.59% |
| Perf YTD | −2.32% |
| Prev Day | −1.74% |
| Clavix | B |
| Debt / Eq | 0.35 |
| Curr Ratio | 1.87 |
| Int Cover | 13.3× |
| FCF Margin | 21.4% |
| Rev Growth | +2.9% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 8 / 19 |
What DHR does
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions.
The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands.
The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984.
Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Clavix risk grade
regraded every trading dayDHR grades B, 75.5 of 100. Steadiest on Macro Resilience (65), most exposed on News Sentiment (53, mixed). 2 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 8 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| DHR | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.79 | 1.18 |
| Volatilityannualized | 19.7% | 29.4% |
| Max drawdown, past yearworst peak-to-trough fall | −33.1% | — |
| Typical daily movemedian absolute daily change | 1.04% | — |
| Days beyond ±3%of the last 252 sessions | 22 (9%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| DHR | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.79 | 1.18 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 53% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| DHR | |
|---|---|
| 1 week | +4.2% |
| 1 month | +7.8% |
| Year to date | −2.3% |
| 1 year | +8.6% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| DHR | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 30 Jul |
| Average score0 most bearish, 100 most bullish | 60 |
| Bullish · bearisharticles above 60 · below 40 | 21 · 3 |
| Directionarticles whose tone is improving vs worsening | 21 ↑ 3 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| DHR | |
|---|---|
| Revenue growthyear over year | +2.9% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openTwenty-three analysts covering Danaher have given the stock a 'Moderate Buy' consensus rating: four said hold, seventeen said buy, and two said strong buy. The article body was truncated and offered no company-specific news beyond these analyst opinions.
Danaher announced a collaboration with NVIDIA to combine its lab instruments, automation, and workflow software with NVIDIA's accelerated computing and AI platforms, and plans to build an AI-powered autonomous lab at Abcam aimed at faster development of custom antibodies and molecular tools.
Danaher announced a collaboration with Nvidia to combine its lab instruments, automation, and software with Nvidia's AI and accelerated computing, aiming to create a learning cycle where experiments inform models and models help design better experiments. Initial work targets a select group of priority instruments using tools like Nvidia DGX Spark, RAPIDS, and BioNeMo Open Models.
Danaher announced a new partnership with NVIDIA to put AI and accelerated computing into its scientific research tools. The deal focuses on embedding NVIDIA's AI platforms into Danaher's lab instruments to automate and speed up data-heavy experiments, and follows a similar AI push at Abcam.
Danaher's stock rose about 4.7% over the past year to $218.49, but its Q2 2026 results showed only modest growth, with revenue up 5.5% year over year to $6.3 billion and non-GAAP core revenue up 3.0%. The article questions whether the company's improving but still underwhelming growth justifies its current share price.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| TMO | Thermo Fisher Scientific Inc | B+ | $255.1B | 36.62 | 0.86 | Compare |
| A | Agilent Technologies Inc | B | $48.77B | 33.86 | 1.25 | Compare |
| IQV | IQVIA Holdings Inc | B | $43.93B | 31.95 | 1.18 | Compare |
| WAT | Waters Corp | B+ | $43.78B | 263.53 | 1.16 | Compare |
| ILMN | Illumina Inc | B- | $39.64B | 48.05 | 1.43 | Compare |
| MTD | Mettler-toledo International Inc | B+ | $32.51B | 35.89 | 1.19 | Compare |
| WST | West Pharmaceutical Services Inc | A- | $23.90B | 49.78 | 1.15 | Compare |
| MEDP | Medpace Holdings Inc | B | $17.26B | 35.12 | 1.11 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.